PER 2.35% 8.7¢ percheron therapeutics limited

Ann: Intention to launch Share Purchase Plan, page-59

  1. 69 Posts.
    lightbulb Created with Sketch. 51
    I was just trying to correct/get a re-think on the way EV was being calculated. I am not focused on the EV personally.

    For me, EV / MC is a piece of the puzzle for investors, as smart investors will get nervous when funds in the bank are short.

    That said, I am focused on key drivers / overall picture:

    1. we are funded to the end of these trails
    2. we have timelines (around this time next year for the news from the trails) - July 2024 approx
    3. the drug works by itself and/or in combination with other drugs/therapies
    4. fast track approval as a break through drug is possible once the trials complete and confirm the findings in previous trials
    5. potential in both stages of DMD - ambulatory and non ambulatory boys
    6. inflammation is the key cause of so much! Potentially can be used on other illnesses - increasing the ability to earn dollars. DMD patients are estimated to need to spend $200K per year per person.

    I wish I could fast forward two years into the future!

 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.7¢
Change
0.002(2.35%)
Mkt cap ! $78.43M
Open High Low Value Volume
8.6¢ 8.9¢ 8.5¢ $53.40K 614.3K

Buyers (Bids)

No. Vol. Price($)
1 49999 8.7¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 67263 1
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.